Isla Garraway MD PhD
Associate Professor and Director of Research, Department of Urology, David Geffen School of Medicine at UCLA
Join to view full profile
10833 LeConte Ave., 66-134 CHSLos Angeles, CA 90095
Phone+1 310-206-4890
Fax+1 310-206-4890
Dr. Garraway is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Urology, 1999 - 2005
David Geffen School of Medicine at UCLAClass of 1989
Certifications & Licensure
CA State Medical License 2001 - 2028
MA State Medical License 2026 - 2026
American Board of Urology Urology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Publications & Presentations
PubMed
- Interference of clonal hematopoiesis in cfDNA liquid biopsy testing and identification of actionable alterations in large diverse cohort of US veterans.Luca F Valle, Micaela Scobie, Kerry Rowe, Colin C Pritchard, Bruce Montgomery
The Oncologist. 2026-07-08 - Prostate-Specific Antigen Screening Patterns and Metastatic Prostate Cancer in US Veterans.Mehrnaz Siavoshi, Stephen Frochen, Mary Fakunle, Ananta Wadhwa, Ashley-Marie Y Green-Lott
JAMA Network Open. 2026-07-01 - Equity and Cancer Survival Among Veterans Health Administration Patients: A Systematic Review and Meta-Analysis.Alyssa Jasmine Bullard, Haley I Tupper, Kevin Su, Lin Gu, Luca F Valle
JAMA Network Open. 2026-07-01
Journal Articles
- ONECUT2 Is a Targetable Master Regulator of Lethal Prostate Cancer That Suppresses the Androgen AxisIsla P Garraway, Michael R Freeman, Alberto Yanez, Nature
Press Mentions
Oncology Drugs Fast-Tracked by the FDA in May 2025June 13th, 2025- Non-Surgical Option Approved for Recurrent Low-Grade Bladder CancerJune 12th, 2025
- Genomic Testing Reveals Distinct Mutation Patterns in Black and White Veterans with Metastatic Prostate CancerJune 4th, 2025
Grant Support
- Creating precision in metastatic hormone sensitive prostate cancer: Using tumor genetics and patient characteristics to predict outcomes and improve treatment selectionST. LOUIS VA MEDICAL CENTER2025–2029
- Multi-level factors impacting clinical outcomes in Veterans with low-/intermediate-risk prostate cancerVA GREATER LOS ANGELES HEALTHCARE SYSTEM2025–2029
- Predicting Metastatic Progression of High Risk Localized Prostate CancerVA GREATER LOS ANGELES HEALTHCARE SYSTEM2023–2027
- Mechanisms of Prostate Cancer MetastasisCEDARS-SINAI MEDICAL CENTER2021–2026
- Mechanisms of Prostate Cancer MetastasisCEDARS-SINAI MEDICAL CENTER2021–2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
